The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

– Clinical trial builds on encouraging Phase 1 data of monotherapy VIR-5500 in late-line patients presented in January 2025 "We are excited to advance our VIR-5500 Phase 1 trial with the addition of ...

In patients with prostate cancer, androgen receptor pathway inhibitors (ARPIs) extended the median time to no longer clinically benefitting (NLCB) to 11.1 months compared with the 6.9 months seen with ...

Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited ...

The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for ...